General Clinical Chemistry Analyzers and Accessories
Abcam 4'-hydro x yazobenzene-2-carbo x ylic acid (HABA), 1G
MW 242.23 Da. An endogenous metabolite. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CHIR-124, 5MG
MW 419.9 Da, Purity >98%. Novel and potent Chk1 inhibitor (IC₅₀ = 0.3 nM), 2,000-fold more potent than Chk2 (IC₅₀ = 0.7 μM). Also, potently targets other kinases such as FLT3 (IC₅₀ = 5.8 nM), PDGFR (IC₅₀ = 6.6 nM), GSK-3 (IC₅₀ = 23.3 nM) and Fyn (IC₅₀ = 98.8 nM) .
The product is subject to the following: Abcam Restricted Use Statement
Abcam Calcein Blue AM acetate, 1MG
MW 465.4 Da, Purity >95%. Blue fluorescent cell viability probe which won't overlap with green fluorescence from other probes. Penetrates live cell membranes and is virtually non-fluorescent. Upon ubiquitous esterase enzyme activity it produces a bright blue fluorescent that is trapped in live cells - convenient for measurement by epifluorescence light microscopy or flow cytometry. Useful to measure the total number of live versus dead cells - dye leaks out quickly due to the compromised membrane in dead cells resulting in no staining.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GSK2656157, 5MG
MW 416.5 Da, Purity >=98%. Potent and selective PERK inhibitor (IC₅₀ = 0.9 nM in cell-free assay). ATP-competitive. Exibits 500-fold selectivity for PERK versus a panel of 300 kinases.
The product is subject to the following: Abcam Restricted Use Statement
Abcam URMC-099, 25MG
MW 421.5 Da, Purity >98%. Novel orally bioavailable, brain penetrant mixed lineage kinase (MLK) inhibitor (IC₅₀ values of 19, 42, 14, and 150 nM for MLK1, MLK2, MLK3, and the related MLK family member DLK, respectively). Inhibits multiple kinase pathways including LRRK2 (IC₅₀ = 11 nM). Decreases the production of inflammatory cytokines in cultured microglia exposed to HIV-1 Tat. Reduces fMLP-induced chemotaxis of neutrophil from wild-type C57Bl/6 mice. Facilitates Amyloid-β Clearance in a Murine Model of Alzheimer's Disease.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SRT1720 hydrochloride, 5MG
MW 506 Da, Purity >=98%. Selective SIRT1 activator (EC₅₀ = 0.16 μM), 230-fold less potent for SIRT2 and SIRT3. Induce autophagy.
The product is subject to the following: Abcam Restricted Use Statement
Abcam ML 204, TRPC4 blocker, 25MG
MW 226.32 Da. Selective TRPC4 channel blocker (IC₅₀ = 0.96 (fluorescence assay) - 2.6 μM (electrophysiological assay)). Selective versus TRPC6 (19-fold) and TRPC5 (9-fold). Essentially inactive at TRPV1, TRPV3, TRPA1 and TRPM8 channels at concentrations up to 22 μM.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CHIR-124, 25MG
MW 419.9 Da, Purity >98%. Novel and potent Chk1 inhibitor (IC₅₀ = 0.3 nM), 2,000-fold more potent than Chk2 (IC₅₀ = 0.7 μM). Also, potently targets other kinases such as FLT3 (IC₅₀ = 5.8 nM), PDGFR (IC₅₀ = 6.6 nM), GSK-3 (IC₅₀ = 23.3 nM) and Fyn (IC₅₀ = 98.8 nM) .
The product is subject to the following: Abcam Restricted Use Statement
Abcam 2', 7'-Dichlorofluorescein di-ß-D-lactoside, 5MG
MW 1049.76 g/mol. Highly sensitive fluorescent substrate for measuring beta-lactosidase and glucosidase inside live cells. Retains fluorescence at low pH due to lower pKa than comparable fluorophores. Suitable for measuring activity in the acidic lysosome environment.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Sonidegib (NVP-LDE225, Erismodegib), smoothened (Smo) antagonist, 100MG
MW 485.5 Da. Potent and selective Smoothened antagonist. Blocks Hedgehog signaling pathway activity (IC₅₀ = 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays. Anti-tumor activity in mouse medulloblastoma allograft model.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Vistusertib (AZD2014), 5MG
MW 462.5 Da, Purity >98%. Novel potent and selective mammalian rapamycin (mTOR) inhibitor (IC₅₀ = 2.8 nM). Highly selective against multiple PI3K isoforms. Also targets P-Akt (IC₅₀ = 80 nM) and pS6 (IC₅₀ = 200 nM). An oral inhibitor with potential anti-neoplastic activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Vistusertib (AZD2014), 10MG
MW 462.5 Da, Purity >98%. Novel potent and selective mammalian rapamycin (mTOR) inhibitor (IC₅₀ = 2.8 nM). Highly selective against multiple PI3K isoforms. Also targets P-Akt (IC₅₀ = 80 nM) and pS6 (IC₅₀ = 200 nM). An oral inhibitor with potential anti-neoplastic activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ganetespib (STA-9090), 25MG
MW 364.4 Da, Purity >98%. Potent Hsp90 inhibitor (IC₅₀ of 4nM in OSA 8 cells). Causes cytotoxicity in a variety of hematological and solid tumor cell lines by causing degradation of multiple oncogenic Hsp90 client proteins. Ganetespib inhibits MG63 cell lines with IC₅₀ of 43 nM.
The product is subject to the following: Abcam Restricted Use Statement
Abcam PF-573228, 50MG
MW 491.5 Da, Purity >=98%. Potent and selective FAK inhibitor (IC₅₀ = 4 nM versus recombunant catalytic fragent). Blocks FAK Tyr397phosphorylation in cultured cells (IC₅₀ = 30–100 nM). Shows 50 - 250-fold selectivity for FAK aginst a panel of 40 recombinant kinases. Inhibits chemotactic and haptotactic cell migration.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AZ-20, 5MG
MW 412.5 Da. Potent and selective ATR kinase inhibitor (IC₅₀ = 5 nM in vitro; IC₅₀ = 50 nM in carcinoma cell lines). Selective versus mTOR (8-fold). Displayed selectivity versus a panel of 442 kinases.Inhibits LoVo colorectal adenocarcinoma tumor cell growth.
The product is subject to the following: Abcam Restricted Use Statement